# The deal is one of the latest for China's biotech sector amid increasing interest from foreign drugmakers.

*biotech · news · 2026-06-01 · Reuters*

## Key points

- Lilly has signed a licensing deal with a Haisco unit for innovative drug projects.
- Lilly obtains worldwide rights to certain Haisco assets except in Greater China regions.
- Haisco's unit will receive up to $87 million in upfront and near-term payments from Lilly.
- The deal could yield roughly $3 billion in additional milestone-based payments to the Haisco unit.

The deal is ⁠one of the latest for China's ​biotech sector amid increasing interest from foreign ​drugmakers in local businesses' development pipelines, and marks an expansion of collaborations for Lilly itself. Sign up here. The latest deal with ‌the ⁠Haisco unit covers innovative drug projects, Haisco said in a filing to the Shenzhen stock exchange. Under the terms, Lilly ​will secure ​worldwide rights ⁠to select Haisco unit assets outside mainland China, Hong Kong, ​Macau and Taiwan. The unit is ​eligible ⁠to receive up to $87 million in upfront and near-term payments, and up to ⁠about $3 ​billion in additional payments ​tied to clinical, regulatory and commercialisation-related milestones. Reporting by Andrew ​Silver in Hangzhou, Editing by Louise Heavens

**Companies:** Lilly, Haisco
**Countries:** China

[Read the full story on Reuters](https://www.reuters.com/legal/litigation/unit-chinas-haisco-eli-lilly-sign-collaboration-licensing-deals-2026-06-01/)

---

Canonical: https://newsio.io/n/af4115d6-5ac4-409a-be62-8d5172425eff/the-deal-is-one-of-the-latest-for-chinas-biotech-sector-amid-increasing-interest
Summarized by Newsio from Reuters. https://newsio.io/how-it-works